1.Impact factors of volume reduction rate of benign thyroid nodules after thermal ablation based on manifestations of conventional ultrasound and contrast-enhanced ultrasound
Lijia WANG ; Ming'an YU ; Shiliang CAO ; Ying WEI ; Zhenlong ZHAO ; Jie WU
Chinese Journal of Interventional Imaging and Therapy 2025;22(5):319-323
Objective To explore the impact factors of volume reduction rate(VRR)of benign thyroid nodules after thermal ablation based on conventional ultrasound and contrast-enhanced ultrasound(CEUS)manifestations.Methods Totally 238 patients with benign thyroid nodules who underwent thermal ablation were retrospectively enrolled and divided into VRR<75%group(n=93)and VRR≥75%group(n=145)according to VRR of lesions 12 months after treatment.Multivariate logistic regression analysis was used to screen the independent impact factors of VRR of lesions 12 months after thermal ablation based on conventional ultrasound and CEUS manifestations.Receiver operating characteristic curve was plotted,the area under the curve(AUC)was calculated to evaluate the efficacy of the combination of the above factors for predicting VRR of lesions.Results High echo,calcification,cystic and solid components,high enhancement,enhancement loss and high ablation energy were all independent risk factors,while circular enhancement was the independent protective factor of VRR of benign thyroid nodules 12 months after thermal ablation(all P<0.05).The AUC of combination of the above factors for predicting VRR of benign thyroid nodules 12 months after thermal ablation was 0.926.Conclusion High echo,calcification,cystic and solid components,high enhancement,enhancement loss and high ablation energy were all independent risk factors,while circular enhancement was the independent protective factor of VRR of benign thyroid nodules 12 months after thermal ablation.
2.Deubiquitinase JOSD2 alleviates colitis by inhibiting inflammation via deubiquitination of IMPDH2 in macrophages.
Xin LIU ; Yi FANG ; Mincong HUANG ; Shiliang TU ; Boan ZHENG ; Hang YUAN ; Peng YU ; Mengyao LAN ; Wu LUO ; Yongqiang ZHOU ; Guorong CHEN ; Zhe SHEN ; Yi WANG ; Guang LIANG
Acta Pharmaceutica Sinica B 2025;15(2):1039-1055
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract, which increases the incidence of colorectal cancer (CRC). In the pathophysiology of IBD, ubiquitination/deubiquitination plays a critical regulatory function. Josephin domain containing 2 (JOSD2), a deubiquitinating enzyme, controls cell proliferation and carcinogenesis. However, its role in IBD remains unknown. Colitis mice model developed by dextran sodium sulfate (DSS) or colon tissues from individuals with ulcerative colitis and Crohn's disease showed a significant upregulation of JOSD2 expression in the macrophages. JOSD2 deficiency exacerbated the phenotypes of DSS-induced colitis by enhancing colon inflammation. DSS-challenged mice with myeloid-specific JOSD2 deletion developed severe colitis after bone marrow transplantation. Mechanistically, JOSD2 binds to the C-terminal of inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) and preferentially cleaves K63-linked polyubiquitin chains at the K134 site, suppressing IMPDH2 activity and preventing activation of nuclear factor kappa B (NF-κB) and inflammation in macrophages. It was also shown that JOSD2 knockout significantly exacerbated increased azoxymethane (AOM)/DSS-induced CRC, and AAV6-mediated JOSD2 overexpression in macrophages prevented the development of colitis in mice. These outcomes reveal a novel role for JOSD2 in colitis through deubiquitinating IMPDH2, suggesting that targeting JOSD2 is a potential strategy for treating IBD.
3.Impact factors of volume reduction rate of benign thyroid nodules after thermal ablation based on manifestations of conventional ultrasound and contrast-enhanced ultrasound
Lijia WANG ; Ming'an YU ; Shiliang CAO ; Ying WEI ; Zhenlong ZHAO ; Jie WU
Chinese Journal of Interventional Imaging and Therapy 2025;22(5):319-323
Objective To explore the impact factors of volume reduction rate(VRR)of benign thyroid nodules after thermal ablation based on conventional ultrasound and contrast-enhanced ultrasound(CEUS)manifestations.Methods Totally 238 patients with benign thyroid nodules who underwent thermal ablation were retrospectively enrolled and divided into VRR<75%group(n=93)and VRR≥75%group(n=145)according to VRR of lesions 12 months after treatment.Multivariate logistic regression analysis was used to screen the independent impact factors of VRR of lesions 12 months after thermal ablation based on conventional ultrasound and CEUS manifestations.Receiver operating characteristic curve was plotted,the area under the curve(AUC)was calculated to evaluate the efficacy of the combination of the above factors for predicting VRR of lesions.Results High echo,calcification,cystic and solid components,high enhancement,enhancement loss and high ablation energy were all independent risk factors,while circular enhancement was the independent protective factor of VRR of benign thyroid nodules 12 months after thermal ablation(all P<0.05).The AUC of combination of the above factors for predicting VRR of benign thyroid nodules 12 months after thermal ablation was 0.926.Conclusion High echo,calcification,cystic and solid components,high enhancement,enhancement loss and high ablation energy were all independent risk factors,while circular enhancement was the independent protective factor of VRR of benign thyroid nodules 12 months after thermal ablation.
4.Correction to: Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Rui XIONG ; Leike ZHANG ; Shiliang LI ; Yuan SUN ; Minyi DING ; Yong WANG ; Yongliang ZHAO ; Yan WU ; Weijuan SHANG ; Xiaming JIANG ; Jiwei SHAN ; Zihao SHEN ; Yi TONG ; Liuxin XU ; Yu CHEN ; Yingle LIU ; Gang ZOU ; Dimitri LAVILLETTE ; Zhenjiang ZHAO ; Rui WANG ; Lili ZHU ; Gengfu XIAO ; Ke LAN ; Honglin LI ; Ke XU
Protein & Cell 2022;13(10):778-778
5.Evaluation of antibody responses to two-dose inactivated SARS-CoV-2 vaccines in patients with HIV-1 or chronic HBV infection: a single-center retrospective cohort study
Yan YAN ; Shiliang ZHANG ; Davgadorj CHANTSALMAA ; Wei CHEN ; Bin LIU ; Yong REN ; Xu WANG ; Chunyan LYU ; Lina GE ; Hangyuan WU
Chinese Journal of Microbiology and Immunology 2022;42(9):691-698
Objective:To evaluate the efficacy and safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with HIV-1 or chronic HBV infection through observing the dynamic changes in antibody responses to two-dose inactivated SARS-CoV-2 vaccines.Methods:This cohort study recruited 169 people (including 39 with HIV-1 infection, 36 with chronic HBV infection and 94 individuals without chronic diseases) who completed two doses (prime and boost) of inactivated SARS-CoV-2 vaccination from January to December 2021. The levels of SARS-CoV-2 IgM and IgG antibodies at 14 d, one month and two months after boosting and neutralizing antibodies at one month were detected by chemiluminescence immunoassay and competitive ELISA method.Results:The positive rates of antibodies against SARS-CoV-2 in the HIV-1 and HBV groups were higher at one month after booster immunization, but significantly decreases at two months. The double-negative rate of SARS-CoV-2 IgM and IgG antibodies was higher in the HIV-1 and HBV groups than in the control group. The single positive rate of IgG antibody at one month in the control group was 2.01-fold higher than that of the HIV-1 group and 3.17-fold higher than that of the HBV group. The single positive rate of IgG antibody in people aged 18-39 years in each group was higher than that in the 40-59 age group. The antibody persistence was better in the HBV group than in the HIV-1 group, and the levels of IgG antibody in the HBV group was higher than that in the HIV-1 group. The neutralizing capacity of serum antibodies was significantly lower in the HIV-1 group than in the other groups ( P<0.000 1). The inhibition rate of serum neutralizing antibodies in the HBV group was lower than that in the control group among people aged 18-39 years [(34.050±6.031)% vs (64.220±3.845)%, t=4.43, P<0.000 1]. SARS-CoV-2-specific antibody responses were induced in 73.08% (19/26) of the patients aged 18-39 years in the HIV-1 group and 80.00% (4/5) in the HBV group. Conclusions:There were differences in the antibody responses to inactivated SARS-CoV-2 vaccines between different age groups, and infectious diseases affected the positive rates of antibodies and the neutralizing capability against SARS-CoV-2.
6.Correction to: Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Rui XIONG ; Leike ZHANG ; Shiliang LI ; Yuan SUN ; Minyi DING ; Yong WANG ; Yongliang ZHAO ; Yan WU ; Weijuan SHANG ; Xiaming JIANG ; Jiwei SHAN ; Zihao SHEN ; Yi TONG ; Liuxin XU ; Yu CHEN ; Yingle LIU ; Gang ZOU ; Dimitri LAVILLETE ; Zhenjiang ZHAO ; Rui WANG ; Lili ZHU ; Gengfu XIAO ; Ke LAN ; Honglin LI ; Ke XU
Protein & Cell 2021;12(1):76-80
7.The Biomechanical Influence of Angled Abutment in Dental Implants: A Review
Yuqi WANG ; Kebin TIAN ; Shiliang WU
Journal of Medical Biomechanics 2020;35(3):E391-E396
The influence of angled abutments on stress of peri-implant bone is a controversial issue. It is widely accepted that the use of angled abutments will increase adverse stress distributions on implants and surrounding bones. However, comparisons of clinical success rates of implants restored with angled and straight abutments indicate no significant differences. This review summarized the clinical application and biomechanical research associated with angled abutments. The use of angled abutments did not detrimentally affect the retention of dental implants, and tt was possible that the magnitude of stress within peri-implant bone increased or decreased under different conditions. Therefore, further researches should be conducted to confirm that favorable peri-implant stress levels may be induced if suitable angulation of abutments is selected.
8.Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Rui XIONG ; Leike ZHANG ; Shiliang LI ; Yuan SUN ; Minyi DING ; Yong WANG ; Yongliang ZHAO ; Yan WU ; Weijuan SHANG ; Xiaming JIANG ; Jiwei SHAN ; Zihao SHEN ; Yi TONG ; Liuxin XU ; Yu CHEN ; Yingle LIU ; Gang ZOU ; Dimitri LAVILLETE ; Zhenjiang ZHAO ; Rui WANG ; Lili ZHU ; Gengfu XIAO ; Ke LAN ; Honglin LI ; Ke XU
Protein & Cell 2020;11(10):723-739
Emerging and re-emerging RNA viruses occasionally cause epidemics and pandemics worldwide, such as the on-going outbreak of the novel coronavirus SARS-CoV-2. Herein, we identified two potent inhibitors of human DHODH, S312 and S416, with favorable drug-likeness and pharmacokinetic profiles, which all showed broad-spectrum antiviral effects against various RNA viruses, including influenza A virus, Zika virus, Ebola virus, and particularly against SARS-CoV-2. Notably, S416 is reported to be the most potent inhibitor so far with an EC of 17 nmol/L and an SI value of 10,505.88 in infected cells. Our results are the first to validate that DHODH is an attractive host target through high antiviral efficacy in vivo and low virus replication in DHODH knock-out cells. This work demonstrates that both S312/S416 and old drugs (Leflunomide/Teriflunomide) with dual actions of antiviral and immuno-regulation may have clinical potentials to cure SARS-CoV-2 or other RNA viruses circulating worldwide, no matter such viruses are mutated or not.
Animals
;
Antiviral Agents
;
pharmacology
;
therapeutic use
;
Betacoronavirus
;
drug effects
;
physiology
;
Binding Sites
;
drug effects
;
Cell Line
;
Coronavirus Infections
;
drug therapy
;
virology
;
Crotonates
;
pharmacology
;
Cytokine Release Syndrome
;
drug therapy
;
Drug Evaluation, Preclinical
;
Gene Knockout Techniques
;
Humans
;
Influenza A virus
;
drug effects
;
Leflunomide
;
pharmacology
;
Mice
;
Mice, Inbred BALB C
;
Orthomyxoviridae Infections
;
drug therapy
;
Oseltamivir
;
therapeutic use
;
Oxidoreductases
;
antagonists & inhibitors
;
metabolism
;
Pandemics
;
Pneumonia, Viral
;
drug therapy
;
virology
;
Protein Binding
;
drug effects
;
Pyrimidines
;
biosynthesis
;
RNA Viruses
;
drug effects
;
physiology
;
Structure-Activity Relationship
;
Toluidines
;
pharmacology
;
Ubiquinone
;
metabolism
;
Virus Replication
;
drug effects
9.Expression of PD-1hiCXCR5-CD4+T cells in patients with systemic lupus erythematosus
Shiliang ZHOU ; Ting XU ; Mingyuan CAI ; Like ZHUANG ; Lu ZHANG ; Jinyun CHEN ; Peirong ZHANG ; Rurong SUN ; Wen XIE ; Yingchun MA ; Min WU
Chinese Journal of Rheumatology 2019;23(1):15-18
Objective To investigate the expression of peripheral programmed death (PD)-1hiCXCR5-CD4+T cells and its clinical significance in systemic lupus erythematosus (SLE). Methods Peripheral blood PD-1hiCXCR5-CD4+ T cells from 21 SLE patients and 16 healthy controls were examined by flow cytometry. The levels of serum anti-double-stranded deoxyribonucleic acid (dsDNA) antibodies were determined using immunoradiometric as-say. Data were analyzed with t test and Pearson's correlation test. Results The per-centages of PD-1hiCXCR5- cells within CD4+ T cell were significantly higher in SLE patients [(2.1 ±2.0)%] compared to normal controls [(0.3±0.3)%] (t=2.959, P<0.01). The percentages of PD-1hiCXCR5-cells within CD4+T cells in moderate to severe active SLE patients (3.0 ±2.0)% was significantly increased compared to patients with mild or inactive (1.0±1.4)%(t=2.574, P<0.05) and normal controls (0.3±0.3)% (t=5.149, P<0.01). The percentages of PD-1hiCXCR5- cells within CD4+ T cells from SLE patients were positively related with systemic lupus erythematosus disease activity index (SLEDAI) (r=0.475, P=0.0297). SLE patients in serum anti-dsDNA antibodies positive group (2.7±2.1)%displayed a higher percentage of PD-1hiCXCR5-cells within CD4+T cells than patients in serum anti-dsDNA antibodies negative group (0.6 ±0.5)% (t=2.303, P<0.05). The percentages of PD-1hiCXCR5-cells within CD4+T cells from SLE patients were positively correlated with anti-dsDNA antibody titers. Conclusion The percentages of PD-1hiCXCR5- cells within CD4+ T cells from SLE patients are increased and are positively correlated with SLEDAI and anti-dsDNA antibody levels. Increased percentage of PD-1hiCXCR5-cells within CD4+T cells might play an important role in the pathogenesis of SLE.
10.The surgical treatment for complex vesicovaginal fistula
Yuke CHEN ; Yang YANG ; Wei YU ; Jihong DUAN ; Yunxiang XIAO ; Shiliang WU
Chinese Journal of Urology 2017;38(10):737-740
Objective To discuss the outcomes of transvaginal repair and transabdominal repair for complex vesicovaginal fistula (VVF).Methods The data of complex VVF patients undergoing surgical repair in Peking University First Hospital were retrospectively collected between January 2009 and December 2016.The surgical modalities for complex VVF included transvaginal repair with layered closure and transabdominal repair with full thick vascular peritoneal interposition.The subtype distribution of complex VVF in transabdominal repair group and transvaginal repair group were recorded.The present study included 63 complex VVF patients with the median age of 46 years (range 26-60 years).There were 32 cases undergoing transvaginal repair with layered closure and 31 cases undergoing transabdominal repair with full thick vascular peritoneal interposition.The proportion of cases having failed previous repairs was significantly higher in transvagical repair group (30/32 vs.23/31,P =0.034).Compared with patients with transvaginal repair,patients with transabdominal repair tended to have multiple VVF without statistic significance (18.8% vs.29.0%,P =0.338).Patients with transabdominal repair had larger VVF than patients with transvaginal repair (median:1.0cm vs.0.5cm,P < 0.001).Results There were 2 cases suffering from fat liquefaction of surgical incision and 1 case suffering from adhesive intestinal obstruction in patients undergoing transabdominal repair.In the median follow-up duration of 24 months (range 8-102 months)and 29 months (range 8-78 months),the successful rates of transvaginal repair and transabdominal repair were 75% (24/32) and 93.5% (29/31).Severe lower urinary tract symptoms occurred in one patient who had urine leakage after transabdomnal repair.The bladder volume of patients in transabdominal group recovered at postoperative 3-6 months.Conclusions In consideration of surgical invasion and fistula condition,transvaginal repair with layered closure and transabdominal repair with full thick vascular peritoneal interposition should be performed individually for complex VVF.Meanwhile,the surgeons need pay attention to other perioperative management.

Result Analysis
Print
Save
E-mail